We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Kowa Study

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week, Phase 2 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Patients with Fuchs Endothelial Corneal Dystrophy

Purpose of the Study

This is a multi-center, double-masked, randomized, parallel-group, placebo-controlled, 2-period study of patients with FECD after descemetorhexis.

Basic Eligibility Criteria

  • Age 18 or older
  • Diagnosed with Fuchs endothelial corneal dystrophy

How to Contact Us

Principal Investigator: Dr. Ahmed Omar
Study contact: Leslie Richards I 216-844-0794